Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
6.33
-0.23 (-3.51%)
Sep 23, 2026, 3:04 PM CST
Xiangxue Pharmaceutical Revenue
Xiangxue Pharmaceutical had revenue of 348.62M CNY in the quarter ending June 30, 2026, a decrease of -12.19%. This brings the company's revenue in the last twelve months to 1.48B, down -6.32% year-over-year. In the year 2025, Xiangxue Pharmaceutical had annual revenue of 1.60B, down -14.16%.
Revenue (ttm)
1.48B
Revenue Growth
-6.32%
P/S Ratio
2.83
Revenue / Employee
556.04K
Employees
2,662
Market Cap
4.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | -263.25M | -14.16% |
| Dec 31, 2024 | 1.86B | -440.63M | -19.16% |
| Dec 31, 2023 | 2.30B | 112.22M | 5.13% |
| Jan 1, 2023 | 2.19B | -783.51M | -26.38% |
| Jan 1, 2022 | 2.97B | -101.51M | -3.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Wuhan Hvsen Biotechnology | 1.72B |
| Hefei Lifeon Pharmaceutical | 1.51B |
| Shenzhen Weiguang Biological Products | 1.20B |
| Beijing Konruns Pharmaceutical | 917.05M |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |
| Landfar Bio-medicine | 660.26M |
| Beijing Scitop Bio-tech | 372.08M |